Pierre Fabre to cut jobs in pharma to focus on cosmetics division abroad

By Michelle Yeomans

- Last updated on GMT

Pierre Fabre to cut jobs in pharma to focus on cosmetics division abroad

Related tags Medicine Pharmacology

Pierre Fabre is cutting 551 jobs in pharmaceutical research and development and sales by 2016, almost exclusively in France, as it focuses on expanding its cosmetics division abroad.

Unveiling its five year strategy, the France based company says it aims to cut costs in pharmaceuticals to grow its dermo-cosmetics business abroad, particularly in Asia and the US.

A spokesman for Pierre Fabre said 534 of the planned job cuts will be in France and the remainder would result from the closure of an R&D site in Barcelona.

The company's portfolio which sells in over 130 countries, includes brands like Avène, Klorane, Ducray, Rene Furterer and Drill.

Cosmetics division accounts for 55% of group revenue 

Pierre Fabre has 6,500 staff in France out of 10,000 worldwide, said it would seek to avoid layoffs by offering affected employees other jobs within or outside the company.

According to Reuters, the cosmetics division accounts for 55% of group revenue and the bulk of its profit, whereas the pharmaceuticals division has seen sales fall in France since 2009.

In a recent statement, the company announced it will be focusing its R&D on dermatology, oncology and neuropsychiatry, cutting 272 jobs in southern France, which have been "insufficiently productive" up to now.

Reuters analysts report the former CEO of top French drugmaker Sanofi, Chris Viehbacher, made the same reproach to his company's R&D site in Toulouse in 2012, sparking outrage from unions and the government. Sanofi finally agreed last week to hand over the site to German outsourcing firm Evotec.

Pierre Fabre's work in cosmetics

Back in 2009, Pierre Fabre invested €71m in its manufacturing facilities near Castres, creating 150 new jobs to increase production of its' dermo-cosmetics products.

Its' plans then were to invest €71m and increase its production capacity by 60m units and develop its activities this division, especially in international markets.

The company already had a number of dermo-cosmetic brands under its belt at the time including Klorane, Avène and Glytone and continues to carry out skin care research in the area of ageing, inflammation, pigmentation and the barrier function.

Related topics Business & Financial Skin Care

Related news

Related products

show more

Get your skin ready for summer

Get your skin ready for summer

Content provided by Robertet Health & Beauty | 27-Jun-2023 | Product Brochure

Sunbathing at the beach is the first UV-related skin damage that comes to mind. Whereas, enjoying a coffee on a terrace under the sun can be as harmful.

Tagra Launches New Water-Soluble Biotin Revolution

Tagra Launches New Water-Soluble Biotin Revolution

Content provided by Tagra Biotechnologies | 05-Apr-2023 | Product Presentation

Biotin (vitamin B7) helps improve hair health, skin’s pigmentation, and nail’s appearance. Biotin occurs as a crystalline powder with very little solubility...